This antibody-drug conjugate exhibited efficient tumor killing in pre-clinical in vivo models, and was safe in a phase I clinical trial in AML, even at drug doses saturating the CD33 binding sites (75 mg/m2 × 2), potentially making it a safer option for CAR T therapy (17, 18). Here, CD33 is linked to acute myeloid leukemia.